drugset / Trial / NCT01048203

A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

NCT01048203

Phase 1 Completed 6 enrolled Active Biotech AB
NaSingle-groupOpen-label

Summary

This is a single site, open label, single dose, non-randomized study in healthy male and female subjects. The subjects will be evaluated for plasma, urine and feces levels of 14C-ABR-215050 during 21 days.

Timeline

Start
2009-01
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tasquinimod Small molecule 1 mg Oral

Indications

No indication recorded.